A preclinical feasibility study has shown that epinephrine delivered nasally (without needles) was absorbed into the bloodstream with similar effectiveness as epinephrine delivered traditionally via auto-injector, according to a press release by partner pharmaceutical companies.
Shin Nippon Biomedical Laboratories, Ltd of Japan and G2B Pharma Inc of San Francisco have cleared the way to begin clinical trials in 2014 of a new system for administering emergency epinephrine in cases of suspected anaphylaxis. The system is comprised of a novel nasal delivery system as well as a proprietary epinephrine formulation.
Though FDA approval is still years away, an alternate means of delivering epinephrine that does not involve needles would be welcome. Epinephrine is often administered too late in spite of the fact that the drug carries little risk of side effects because parents are afraid to “stab” their children with an auto-injector. A means of delivering epinephrine painlessly may allay fears of administering the drug at the first sign of anaphylactic symptoms.